wonderisland / Shutterstock.com
Novartis has sued drug company BPI Labs for alleged patent infringement after it requested permission to market a generic version of Novartis’s bone cancer drug Zometa (zoledronic acid).
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Novartis, BPI Labs, Zometa, ANDA, US District Court for the Middle District of Florida, zoledronic acid